These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 6304570

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment of chronic congestive cardiac insufficiency with an orally active inhibitor of the angiotensin converting enzyme (Captopril)].
    Guerrera G, Melina D.
    Minerva Cardioangiol; 1983 Mar; 31(3):93-100. PubMed ID: 6304571
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of moderate to severe hypertensive patients with an orally active converting-enzyme inhibitor.
    Prins EJ, Donker AJ, Hoorntje SJ, Leenen FH, van der Hem GK.
    Proc Eur Dial Transplant Assoc; 1979 Mar; 16():603-9. PubMed ID: 232914
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Usefulness of orally active angiotensin I converting enzyme inhibitor (SQ 14,225) in the treatment of malignant hypertension.
    Abe I, Kawasaki T, Ueno M, Kawano Y, Uezono K, Ogata M, Kawazoe N, Omae T, Fukiyama K.
    Fukuoka Igaku Zasshi; 1980 Mar; 71(3):157-66. PubMed ID: 6247259
    [No Abstract] [Full Text] [Related]

  • 6. [A new point of attack for the treatment of hypertension; captopril, an orally active inhibitor of the enzymatic conversion of angiotensin I into angiotensin II].
    Schalekamp MA, de Bruyn JH, Wenting GJ, Man in 't Veld AJ, Derkx FH.
    Ned Tijdschr Geneeskd; 1980 Nov 22; 124(47):1996-2003. PubMed ID: 6255350
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Use of SQ 14225 in the treatment of essential arterial hypertension].
    Degli Esposti E, Chiarini C, Fusaroli M, Masi A, Santoro A, Sturani A, Zuccalà A, Zucchelli P.
    Clin Ter; 1981 Apr 30; 97(2):153-63. PubMed ID: 6263540
    [No Abstract] [Full Text] [Related]

  • 10. First dose effect of the oral angiotensin converting enzyme inhibitor captopril.
    Fagard R, Amery A, Lijnen P, Staessen J.
    Arch Int Pharmacodyn Ther; 1980 Apr 30; Suppl():178-87. PubMed ID: 6251761
    [Abstract] [Full Text] [Related]

  • 11. Use of angiotensin I to II converting enzyme inhibitor S.Q. 14225 (captopril), in moderate essential hypertension.
    Ryan E, Muldowney FP.
    Ir Med J; 1983 Apr 30; 76(4):175, 177-8. PubMed ID: 6345457
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment of hypertensive crisis with captopril].
    Biollaz J, Waeber B, Turini GA, Schaller MD, Brunner HR.
    Schweiz Med Wochenschr; 1983 Dec 31; 113(52):2006-7. PubMed ID: 6364338
    [Abstract] [Full Text] [Related]

  • 14. Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension.
    Aberg H, Frithz G, Mörlin C.
    Int J Clin Pharmacol Ther Toxicol; 1981 Aug 31; 19(8):368-71. PubMed ID: 7030977
    [Abstract] [Full Text] [Related]

  • 15. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP, Karlberg BE, Nilsson OR, Wettre S.
    Acta Med Scand Suppl; 1981 Aug 31; 646():98-105. PubMed ID: 7018190
    [Abstract] [Full Text] [Related]

  • 16. [Effect and tolerance of the angiotensin-converting enzyme inhibitor captopril (Tensobon)].
    Rahn KH, Stumpe KO.
    MMW Munch Med Wochenschr; 1984 Feb 22; 126 Suppl 1():S5-14. PubMed ID: 6323979
    [No Abstract] [Full Text] [Related]

  • 17. [Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients (author's transl)].
    Mizuno K, Gotoh M, Shigetomi S, Matsui J, Tsutsui K, Ogata M, Fukuchi S.
    Nihon Jinzo Gakkai Shi; 1981 Aug 22; 23(8):1113-21. PubMed ID: 7033606
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical experience with an oral converting-enzyme inhibitor (Captopril) in hypertensive subjects].
    Pierucci A, Simonetti BM, Feriozzi S, Stirati G, Cinotti GA.
    Minerva Nefrol; 1981 Aug 22; 28(3):271-3. PubMed ID: 7036016
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment of refractory arterial hypertension with a converting enzyme inhibiting drug (Captopril)].
    Lavezzaro GC, Angelino PF, Gastaldo D, Minelli M, Paccotti P, Angeli A.
    Minerva Cardioangiol; 1981 Oct 22; 29(10):519-25. PubMed ID: 7033830
    [No Abstract] [Full Text] [Related]

  • 20. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
    MacGregor GA, Markandu ND, Roulston JE, Jones JC.
    Br Med J; 1979 Nov 03; 2(6198):1106-9. PubMed ID: 229941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.